Alder BioPharmaceuticals Inc
Most Recent
Competition Dynamics for Ajovy—Teva’s Migraine Drug
Approved by the FDA on September 14, Teva’s Ajovy has multiple competitors set to enter the market.
What’s the Latest on Teva’s Fremanezumab?
Teva’s (TEVA) much-awaited migraine drug, Fremanezumab, is in late-stage trials for the treatment of cluster headaches.
What Will Help Eli Lilly Build a Stronger Migraine Portfolio?
In September, Eli Lilly presented the results of its phase-3 Spartan trial, in which Lasmiditan demonstrated significant progress in the treatment of migraines.
Biotechnology ETFs: Who Were the Top Performers Last Week?
Biotechnology ETFs rose during the week ending April 1, 2016. The SPDR S&P Biotech ETF (XBI) and the iShares NASDAQ Biotechnology ETF (IBB) rose 6.2% and 5.0%, respectively.
How are IBB’s Subgroups Performing?
The iShares Nasdaq Biotechnology ETF (IBB) gives good exposure to various industries in the biotechnology industry. As of October 19, IBB rose by ~0.5%.
